All stock lists
Denali Therapeutics Inc. (NASDAQ:DNLI)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
18.66+0.25 (+1.36%)
Insider Score
––Not scored
DNLI Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
DNLI Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 3.60 M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Growth (YoY) | — | — | — | — | — | — |
| Cost of Revenue | 93.00 K | 2.85 M | 2.87 M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 3.51 M | -2.85 M | -2.87 M | 0.00 | 0.00 | 0.00 |
| SG&A Expense | 36.28 M | 30.67 M | 36.59 M | 35.48 M | 32.27 M | 29.35 M |
| R&D Expense | 97.02 M | 103.85 M | 97.91 M | 101.95 M | 102.70 M | 116.23 M |
| Operating Expenses | 134.05 M | 134.51 M | 134.50 M | 137.43 M | 134.96 M | 145.58 M |
| Operating Income | -130.54 M | -137.36 M | -137.37 M | -137.43 M | -134.96 M | -145.58 M |
| Pretax Income | -127.55 M | -128.45 M | -128.45 M | -126.90 M | -124.12 M | -132.97 M |
| Tax Provision | 0.00 | 0.00 | 102.00 K | 0.00 | 0.00 | 0.00 |
| Net Income | -127.55 M | -128.45 M | -128.55 M | -126.90 M | -124.12 M | -132.97 M |
| EPS (Basic) | -0.68 | -0.69 | -0.73 | -0.74 | -0.72 | -0.78 |
| EPS (Diluted) | -0.68 | -0.69 | -0.73 | -0.74 | -0.72 | -0.78 |
| Shares Outstanding | 187.31 M | 186.64 M | 175.46 M | 172.42 M | 171.45 M | 171.22 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.